Premier Path Wealth Partners’s Anavex Life Sciences AVXL Stock Holding History

Premier Path Wealth Partners’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.7K	Hold	10,000	–	–	﹤0.01%	398
2025 Q4	$35.6K	Hold	10,000	–	–	﹤0.01%	394
2025 Q3	$89K	Hold	10,000	–	–	0.01%	391
2025 Q2	$92.2K	Hold	10,000	–	–	0.01%	386
2025 Q1	$85.8K	Sell	10,000 -2,500	-20%	-$23.6K	0.01%	371
2024 Q4	$134K	Hold	12,500	–	–	0.02%	368
2024 Q3	$71K	Hold	12,500	–	–	0.01%	363
2024 Q2	$52.8K	Hold	12,500	–	–	0.01%	367
2024 Q1	$63.6K	Hold	12,500	–	–	0.01%	342
2023 Q4	$116K	Buy	+12,500	New	+$86.1K	0.03%	331

Other funds holding AVXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Premier Path Wealth Partners's AVXL Position: Q1 2026 in Review

Premier Path Wealth Partners held its Anavex Life Sciences (AVXL) position steady in Q1 2026 at 10,000 shares worth $30.7K. The position accounts for ﹤0.01% of the portfolio, ranked #398.

Premier Path Wealth Partners first reported a position in AVXL in Q4 2023 and has held it in 10 quarters since. The position peaked at $134K in Q4 2024. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

Premier Path Wealth Partners held 10,000 shares of Anavex Life Sciences worth $30.7K as of Q1 2026.
Premier Path Wealth Partners left its Anavex Life Sciences share count unchanged in Q1 2026.
Anavex Life Sciences made up ﹤0.01% of Premier Path Wealth Partners's portfolio in Q1 2026, its #398 holding.
Premier Path Wealth Partners first reported a position in Anavex Life Sciences in Q4 2023 and has held it in 10 quarters since.
Premier Path Wealth Partners's Anavex Life Sciences position peaked at $134K in Q4 2024.
190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Premier Path Wealth Partners's 13F filing for Q1 2026, filed 23 Apr 2026.